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Myosin light chain phosphatase (MLCP) is an enzyme important to regulation of cell cycle
and motility that is shown to be upregulated in aggressive prostate cancer cells and tissue.
WedevelopedaﬂuorescentsmallmoleculeinhibitorofMLCPusingstructurebaseddesign
in recombinant protein phosphatase 1C. Several best ﬁt compounds were synthesized and
evaluated by their inhibition of MLCP/32P-MLC dephosphorylation, which resulted in the
identiﬁcation of novel MLCP inhibitors. Androgen dependent (AD) and castration resistant
prostate cancer cell (CRPC) lines were treated with the lead inhibitor resulting in decreased
growth rate, reduced DNA synthesis, and G2/M cell cycle arrest. Moreover, CRPC cell lines
showed an increased sensitivity to drug treatment having GI50 values four times lower than
the AD prostate cancer cell line.This was reinforced by reduced BrdU DNA incorporation
into CRPC cells compared to AD cells. β-actin disruption was also seen at much lower drug
concentrations in CR cells which caused a dose dependent reduction in cellular chemotaxis
of PC-3 cells. Since there are currently few clinical therapeutics targeting CR prostate can-
cer, MLCP represents a new target for preclinical and clinical development of new potential
therapeutics which inhibit this disease phenotype.
Keywords: myosin phosphatase, prostate cancer, chemotaxis
INTRODUCTION
Cellularphosphorylationlevelsarecontrolledbyadelicatebalance
between kinase and phosphatase activities. Cancer cells generally
haveupregulatedkinaseactivityandseveralkinaseinhibitorshave
shown promise for controlling the growth or causing the death
of cancer cells (Bridges, 2001; Keneﬁck, 2006). Of the approved
kinase inhibitors for cancer treatment,most have had limited suc-
cess as a monotherapy in patients (Garber, 2006). Inhibition of
phosphatases would allow access to these same targets through a
different mechanism in the effort to expand their clinical viability.
Ourinitialaimofthisstudyistodevelopasmallmoleculeinhibitor
of myosinlightchainphosphatase(MLCP)thatcausesareduction
incancercellgrowth.Creatingsmallmoleculeinhibitorsof MLCP
would target the phosphatase side of the substrate phosphoryla-
tion cycle,which remains relatively untapped for therapeutic pur-
poses and potentially yield new treatments for metastatic cancers.
We designed and synthesized a number of thiazole compounds
targeting the protein phosphatase 1C (PP1C) portion of MLCP
and examined inhibition of MLCP using the enzyme prepared
from pig aorta.
One type of cancer that demonstrates a large treatment dispar-
itybetweenmetastaticandnon-metastaticcasesisprostatecancer.
Prostate cancer cases are classiﬁed based on their dependence on
Abbreviations:AD,androgendependent;BrdU,bromodeoxyuridine;CR,castration
resistant; CRPC,castration resistant prostate cancer; DHT,5α-dihydrotestosterone;
MLCP,myosin light chain phosphatase; MYPT1,myosin targeting subunit 1; PP1C,
protein phosphatase 1 catalytic subunit.
androgen hormones. Androgen dependent (AD) tumors are the
mostcommonpresentationinprostatecancerpatientsandmulti-
ple therapies for this type of prostate cancer exist. Unfortunately,
therapies targeting the AD cells lead to a self selection for cas-
tration resistant prostate cancer (CRPC). Indeed, 80% of men
who undergo androgen ablation therapy return to the clinic 18–
36months after treatment with CRPC. CRPC tumors currently
have few clinical treatments which are limited to chemotherapy
agents. Prostate cancer is a heterogeneous disease whose under-
lying mechanisms of progression and metastasis are unknown.
Current clinical therapies targeting AD prostate cancer drive the
diseasetowardcastrationresistantstatepresentingaclearneedfor
therapies that target CRPC tumors as well as more understanding
of how the disease transitions to a castration resistant state.
Myosin light chain phosphatase is a serine/threonine phos-
phatase that consists of a 130-kDa regulatory subunit that binds
myosin (MYPT1), a 37-kDa catalytic subunit PP1C and a 21-kDa
subunit (M-21) of undetermined function (Hartshorne, 1998).
MLCP is involved in the Rho/ROCK pathway and regulates the
interaction between actin and myosin. MYPT1 is responsible for
determining substrate speciﬁcity via compartmentalization and
allosteric regulation of PP1C. In addition, multiple phosphory-
lation sites of MYPT1 induce activation and inhibition of the
phosphatase activity. Suppression of MYPT1 expression results
in a loss of migration and inhibition of cell growth (Xia et al.,
2005). Cellular PP1 function, such as substrate speciﬁcity and
regulation, is conferred through the interaction with PP1 regu-
latory/targeting subunits MYPT1 is a myosin targeting subunit of
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MLCP, and the extent of MLCP activity relies on the cellular con-
tent of MYPT1(Matsumura and Hartshorne, 2008; Bollen et al.,
2010). MYPT1 is also found in varying levels in breast, ovarian,
stomach, colorectal, and thyroid tumors, but its function in those
tumor tissues has not been fully explored.
Protein phosphatase 1C, the catalytic subunit of MLCP, is a
member of the phospho-protein phosphatase (PPP) superfamily
of phosphatases. Other major members of the PPP family include
PP1, PP2A, and PP2B. PP1C, PP2A, and PP2B share greater than
90% backbone homology as well as 40–50% sequence homology
(Goldberg et al., 1995; Huai et al., 2002). CPI-17 is an endoge-
nous inhibitor of PP1C that, when phosphorylated, is selective
for MLCP over the other PPP family enzymes. There are several
known natural product inhibitor of PP1C – microcystin, okadaic
acid, calyculin, and cantharidin, all of which also inhibit PP2A
(Evans et al., 1992; Humphrey et al., 1996; Forsyth et al., 1997;
Mills et al., 1998; Kita et al., 2002). Enhanced expression of PP1C
isoformsarefoundinmalignanthumantumorcellssuchasbreast
and bone cancer cells (Sogawa et al.,1997).
Inhibition of MLCP catalytic domain causes an increase of
phosphorylation of myosin light chain (MLC, the substrate of
MLCP) in smooth muscle, without kinase activation (Somlyo
and Somlyo, 2003). This increased level of phosphorylated MLC
can alone initiate apoptotic cell death by cell membrane blebbing
(Gupta et al., 1997). Inhibition of MLCP by CPI-17 inhibited cell
spreadingafterreplatingwhichwascausedbylossofcellularmotil-
ity (Forsyth et al.,1997). MLCP inhibition by natural products or
CPI-17canleadtoincreasedMLCphosphorylationresultinginthe
activation of apoptotic machinery, membrane blebbing, and loss
of cellular motility. Suppression of MYPT1 expression results in a
loss of migration and reduced cell growth in both cell adhesion-
dependent and independent soft agar growth assays (Goldberg
et al.,1995). For this reason,development of selective small mole-
cule inhibitors toward MLCP may provide a new pathway for the
prevention and treatment of cancer metastasis.
MATERIALS AND METHODS
CELL CULTURE
Human prostate cancer cell lines CWR22Rv1 (primary prostate
tumor from mouse xenograft, mutant AR, mutant p53), LNCaP
(lymph node metastatic tumor, AR pos, p53 wild type), DU145
(brain metastatic tumor, AR neg, p53 mutant), and PC-3 cells
(bone metastatic tumor, AR neg, p53 null; American Type Cul-
ture Collection) were cultured in RPMI 1640 (Mediatech) con-
taining 10% fetal bovine serum, 2.5mmol/L l-glutamine, and
penicillin–streptomycin(100IU/mLand100μg/mL,respectively)
at 37˚C with 5% CO2. LNCaP cells were cultured in the presence
of 0.5nmol/L dihydrotestosterone (5-α-androstan-17β-ol-3-one;
Sigma-Aldrich). To remove the adherent cells from the ﬂask for
passaging and counting, cells were washed with PBS, incubated
with a small volume of 0.25% trypsin–EDTA solution (Sigma-
Aldrich, St. Louis, MO, USA) for 5–10min, and washed with
culture medium and centrifuged.
AUTHENTICATION OF CULTURED CELL LINES
Asaqualitycontrolandinordertoconﬁrmtheidentityof thecul-
turedcelllinesusedintheseexperiments,celllinesweresubmitted
to genetic ﬁngerprinting. The commercially available Cell IDTM
System (Promega) was used to screen cell lines obtained from
the Georgetown Tissue Culture Shared Resource (LNCaP). Cells
which were obtained from the ATCC (CWR22v1, DU145, PC-3)
were genetically ﬁngerprinted using the PowerPlex 1.2 System by
theATCCandhavebeenpassagedforlessthat6monthsbeforeuse
in these experiments. All cell lines were screened for the presence
of mycoplasmas prior to use by the Georgetown Tissue Culture
SharedResourceusingtheGen-ProbeMycoplasmaTissueCulture
NI Rapid Detection System.
WESTERN BLOT ANALYSIS
Cell pellets were disrupted in lysis buffer (7.4 pH, 5mM EDTA,
50mM NaCl, 30mM sodium pyrophosphate, 50mM sodium
ﬂuoride, 1mM sodium orthovandate, 1mM phenylmethanesul-
fonyl ﬂuoride (Sigma),50μL per 5mL protease cocktail inhibitor
(Sigma), and 1% Triton X-100). The protein samples were sepa-
ratedbySDS-PAGEandweretransferredontoaPVDFmembrane
(Biorad). The membrane was then blocked with a 1% w/v BSA
solution (2.5M NaCl,1M Tris HCl,pH 7.4) for 1h prior to incu-
bation with the primary antibody overnight. Chemiluminescence
measurementwasperformedwithECLdevelopmentkitfollowing
thevendorsinstructions(Perkin-Elmer).Thefollowingantibodies
were purchased from Cell Signaling Technology: PP1α,1:1000. β-
actin(1:10,000)andMLC(1:500)antibodieswerepurchasedfrom
Sigma. MYPT1 (1:1000) antibody was purchased from Upstate.
IMMUNO-HISTOCHEMISTRY
Tissue slices and tissue micro arrays (US Biomax) were deparaf-
ﬁnized,rehydrated,boiled with citrate buffer (pH 6),treated with
0.3% H2O2, and preincubated in blocking solution (10% normal
goat serum). Primary antibody applied to slides at 1:150 dilution
which were incubated for 1h at room temperature. Samples were
incubated with Biotin conjugated anti-rabbit (Vector Labs) sec-
ondaryantibodyat1:200dilutionfor30minatroomtemperature
followed by treatment with DAB chromagen (Dako). Slides were
counterstainedwithHematoxylin(Fisher,HarrisModiﬁedHema-
toxylin). Control slides were evaluated under a light microscope
for Quality Assurance using a known positive tissue and a nega-
tive control consisting of an IHC sample as above while omitting
primary antibody.
MOLECULAR MODELING
The crystal structure of PP1C was obtained from the Protein Data
Bank (structure 1JK7). The binding pocket was deﬁned by a 15-
Å sphere from the residue selection (Arg 96, Ile 130, Ile 133, Tyr
134, Trp 206, Arg 221, and Tyr 272). Candidate molecules were
built in the Sybyl shell and minimized using the conjugate gra-
dient method with 1000 iterations or a stopping point of 0.01kJ
energy differential between conformers. The FlexX suite was then
used to dock the ligands into the binding pocket of PP1C with an
output of 30 conformers.
CHEMICAL SYNTHESIS
All starting material were purchased from Sigma-Aldrich and
used without further puriﬁcation. Suzuki couplings were per-
formed in a 3:1 mixture of dimethoxyethane and water, which
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was degassed with nitrogen for 30min prior to the addition of
the palladium catalyst. Complete synthetic details are available in
Section“Appendix.”
ANALYSIS OF MLCP INHIBITION
Myosin light chain phosphatase activity was measured using
MLCP puriﬁed from pig aorta smooth muscle, which consists of
PP1C and a truncated version of 60-kDa MYPT1 fragment (Eto
etal.,1995).PP1Cwasisolatedfromrabbitskeletalmusclebyace-
tone treatment, as described by Martin et al. (1994). Phosphatase
activity was measured as described previously (Eto et al., 2004).
Twenty kilodalton subunit of smooth muscle myosin regulatory
light chain (LC20), calmodulin, and MLC kinase were prepared
from chicken gizzard by Yoshida and Yagi’s (1988) method. The
isolated LC20 (0.2mg) was phosphorylated for 1h at 30˚C in the
presence of 0.1mM [γ-32P] ATP (50μCi), 50μg/mL calmod-
ulin, and 1.7μg of MCL kinase. The reaction was terminated
by incubation for 5min at 80˚C. Free ATP was removed using
Protein Desalting Spin Column from Pierce, Rockford, IL, USA.
Aliquot of 32P-labeled LC20 was mixed with 2.5mL of Scinti-
Safe30% (Fisher Scientiﬁc, Rockford, IL, USA), and subjected
to scintillation counting to determine the concentration. Phos-
phatase activity was determined by measuring 32P radioactivity
released from the substrate. Conditions were 0.5μM 32P-LC20,
50nM MLCP, 50mM NaCl, 1mM DTT, 0.1mM EDTA, 0.03%
Brij35, 0.5mg/mL leupeitin, 0.1nM okadaic acid, and 25mM
MOPS–NaOH, pH 7.0, in the presence of various concentration
of compound. Okadaic acid was added to avoid a trace activ-
ity of PP2A in the sample. The reaction (20μL) was initiated by
adding MLCP. After a 10-min incubation at 30˚C, the reaction
was terminated by adding 50μL of 20% trichloroacetic acid and
50μLof 0.6%BSA,andthesamplewasplacedonice.Proteinpre-
cipitates were removed by spinning, and the radioactivity of the
released 32P-phosphate in the supernatant was determined using
Beckman LS-6500 scintillation counter. The radioactivity in the
samplewithoutphosphataseandwithenzymeminusinhibitorwas
set as 0 and 100% activity, respectively. Mean value was obtained
from duplicate assay. IC50 ±error value was calculated by a non-
linear regression curve ﬁtting program using an equation: activity
(%)=100−(100×[Inhibitor]/IC50 +[Inhibitor]).
FLUORESCENCE MICROSCOPY OF COMPOUND 17e
PC-3andLNCaPcellswereplatedontosterilizedmicroscopeslides
and incubated overnight. The medium was removed and replaced
withcompletemediumwith20μM17eandincubatedfor60min.
The medium was removed,and the slides were washed four times
with PBS. The cells were then ﬁxed using 4% formaldehyde for
10min. Slides were then washed four times with PBS. The nuclei
were stained with DAPI using mounting medium containing
DAPI. 17e was imaged using a 720-nm excitation using a mul-
tiphoton TiSapphire laser (approximately equivalent to 360nm)
and a 560-nm emission.
GROWTH INHIBITION OF PROSTATE CELLS
LNCaP cells were plated onto a 96-well plate at 20,000 cells per
well and incubated overnight in RPMI medium with 10% FBS,
1%l-glutamine,1%pen/strep,and0.1nMDHT.Themediumwas
removedandreplacedwithserumfreemediumplus17e(ﬁvewells
per concentration) incubation continued for 48h. Ten microliters
of WST-8 reagent solution was added to each well and incubation
continued for 2h. The plate was read using 450nm as the mea-
surementwavelengthand655nmasthereferencewavelength.The
value for the initially plated cells was subtracted and the percent
growth compared to the control was determined. For the andro-
gen independent cell lines,the medium used was RPMI with 10%
FBS, 1% l-glutamine, and 1% pen/strep. CWR22RV1 cells were
plated at 20,000 cells per well. DU145 and PC-3 were all plated at
5,000 cells per well.
BrdU UPTAKE ASSAY
BrdU uptake was determined by using the FITC kit (BD Pharmi-
gen 51-2354AK) and following kit instructions. Cells were plated
onto a six well plate and incubated overnight (500,000 per well
forLNCaP,300,000perwellforCWR22RV1,and200,000perwell
for DU145 and PC-3). The medium was removed and replaced
with serum free medium with 1μM 17e and incubation contin-
ued for 24h. Ten microliters of the BrdU solution was added to
each treated well and incubated for 1h. The cells were trypsinized
and washed twice with PBS and collected by centrifugation. The
cell pellets were ﬁxed with 4% formaldehyde for 10min, perme-
abilized and treated with anti-BrdU antibody for 1h at 25˚C. The
pellets were then submitted for FACS analysis.
CELL CYCLE ANALYSIS
PC-3cellswereplatedat200,000cellsperwellinsixwellplatesand
incubated overnight. The media was then removed and replaced
with serum free media and incubated for 24h. Cells were then
treated with media containing 1μM 17e for treated wells and
serum free media for control wells. Cells were then incubated for
6, 24, and 48h, washed trypsinized and ethanol ﬁxed before sub-
mitting for cells cycle analysis. All values are the average of three
independently calculated experiments.
ANALYSIS OF ACTIN DISRUPTION
PC-3 cells were plated down onto Fluoro view immunoﬂuores-
cence dishes (Fisher) at 100,000 cells per plate using RPMI media
with 10% FBS and allowed to adhere for 48h. LNCaP cells were
plated down at 200,000 cells per dish and allowed to adhere for
24h in RPMI media with 10% FBS and 0.1nM DHT. The media
was then removed and replaced with media containing the appro-
priateconcentrationofcompound17eandallowedtoincubatefor
2h. The cells were the washed twice with PBS and ﬁxed with 4%
formaldehydefor10min.Thecellswerethenwashedanadditional
two times with PBS. For actin staining, the cells were permeabi-
lized for 30min with 0.1% Triton X-100 followed by treatment
with Alexa ﬂuor 680 conjugated phalloidin for 10min.
CHEMOTAXIS ASSAY
The migration assay was performed with the 96-well Boyden
chamber MBA96 (Neuro Probe, Inc., Gaithersburg, MD, USA).
The bottom wells were ﬁlled with 80μL chemo-attractant or neg-
ative control per well and an 8-μm porous membrane was placed
ontop.Thetopwellswerepositionedand200,000cellswereadded
to each well. The chamber was incubated at 37˚C with 5% CO2
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overnight.Thechamberwasdisassembledandthemembranewas
ﬁxed and stained using the Diff-Quik® Stain Set (Dade Behring,
Deerﬁeld,IL,USA).Brieﬂy,themembranewasﬁxedinDiff-Quik®
Fixative for 10min and then placed ﬁrst in Diff-Quik® Solution
I for 3min and then into Diff-Quik® Solution II for 3min. The
membrane was then washed with water three times and the cells
on the upper surface were gently scraped off. The stained mem-
brane was read directly in the spectrophotometer at 595nm using
a 96-well format.
STATISTICAL ANALYSIS
Assays were set up in multiplet (n values noted for each exper-
iment, minimum n =3) and the results were expressed as
mean±SEM. Statistical analysis and p value determination were
done by two-tailed paired t-test with a conﬁdence interval of
95% for determination of the signiﬁcance differences between
treatment groups and was calculated using Sigma Plot software.
p <0.05wasconsideredtobesigniﬁcant.Forimmunohistochem-
icalstaining,thetwo-sidedp valueof Jonckheere–Terpstratestwas
applied as well as a Spearman rank-order correlation coefﬁcient.
For ﬂuorescent intensity analysis, Wilcoxon–Mann–Whitney test
was applied and was represented as a one sided p value.
RESULTS
MLCP EXPRESSION IN PROSTATE CANCER CELL LINES
We investigated the expression levels of the component proteins
that make up MLCP in a prostate cancer cell lines by western blot
analysis for MYPT1 and PP1C. MLCP is critical to the reorgani-
zation of the cellular cytoskeleton during mitosis, so we chose
to examine the expression of MLCP in a progressive cellular
model of prostate cancer to determine if a relationship between
MLCP expression and prostate cancer aggressiveness exists. PC-3
cells have been found to have a higher metastatic potential than
LNCaP cells through a Matrigel invasion assay where PC-3 cells
formed ﬁvefold more colonies than LNCaP cells (Ghosh et al.,
2005). We found that both PP1C and MYPT1 were upregulated
in CRPC cells (CWR22RV1, DU145, PC-3) compared to their
AD counterpart (LNCaP; Figure 1). The CRPC cell lines showed
approximatelya2-to2.5-foldincreaseinPP1Candatwotothree-
fold increase of MYPT1 expression. These cellular models suggest
MLCP is expressed in the more aggressive,CRPC cell types of our
progression model.
MLCP EXPRESSION IN HUMAN PROSTATE CANCER TISSUE
We used MYPT1 as a marker for MLCP expression since no
antibodyfortheMLCPholoenzymeexists.Tosupportourhypoth-
esis that MLCP expression is linked to prostate cancer progres-
sion, we probed various stages of human prostate tumor tissue
for MYPT1 expression. MYPT1 expression in benign, precan-
cerous prostatic intraepithelial neoplasia (PIN) and cancerous
tissues was compared. PIN and cancerous regions showed signif-
icantly higher levels of MYPT1 expression (data not shown). We
employed tissue microarrays (TMAs) to compare MYPT1 expres-
sion across multiple patients presenting various stages of prostate
cancer.
Three TMAs (359 total cores) were stained for MYPT1 expres-
sion and the level of staining was graded on a semiquantitative
scale of low (no staining, 0, or weakly detectable staining, +1,
Figure 2A), medium (+2), and high staining (+3, Figure 2B).
Cores were categorized based on their Gleason’s score into four
categories:normaltissue(n =63),Gleason’s3–6representingpre-
cancerous tissue (n =48), Gleason’s 7 representing the ﬁrst state
of clinically deﬁned prostate cancer (n =68), and Gleason’s 8–
10 representing highly undifferentiated aggressive prostate cancer
(n =180). Prostate tumors with a Gleason’s score of 7 or lower
showed a similar distribution of MYPT1 expression (Figure 2C).
Approximately 60–70% of prostate tissues of Gleason’s score 7
and lower had low to undetectable levels of MYPT1 expression.
Comparing tumors that were graded as a Gleason’s score of 8–10,
approximately35%of thecoresdemonstratedlowtoundetectable
staining showing a two-fold reduction in the percentage of low
stained cores. The percentage of strongly (high) stained cores
increased two to threefold to approximately 30% of the Gleason’s
8–10 core population (p <0.0001).
FLEXIBLE DOCKING OF MLCP INHIBITORS
Withdifferentialexpressionof MLCPinprostatecancerwesought
to design a series of inhibitors to target the catalytic site of MLCP.
Flexible docking of proposed inhibitors onto the X-ray crystal
structure of PP1C (PDB # 1JK7) was performed to assess poten-
tialbindingconformationsintothecatalyticpocketof MLCP.The
crystal structure of full length MLCP has not been solved so the
PP1C structure was used for our analysis. The X-ray crystal struc-
tureofthePP1Ccatalyticpocketiscomprisedofabimetalliccenter
and three adjoining grooves, of which the hydrophilic groove is
FIGURE1|M y osin light chain phosphatase protein content in untreated human prostate cell lines. (A)Western blot analysis of the two main constituent
proteins of MLCP , MYTP1, and PP1C. (B) Densitometry of the Western blot results normalized to LNCaP levels of protein. Error is represented as SEM, n=3.
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FIGURE 2 | Relationship between MYPT1 expression and
Gleason’s score. (A) Representative staining of benign human
prostate tissue. (B) Representative staining of poorly differentiated
human prostate cancer. (C) EachTMA core’s staining was graded and
tabulated in comparison to groupings of Gleason’s scores (normal, 3–6,
7 , and 8–10). MYPT1 staining was seen in increased levels in the
Gleason’s 8–10 grouping.The distributions of the staining are
statistically signiﬁcantly different across the three GS groups
(two-sided p value of Jonckheere–Terpstra test <0.0001).The
estimated Spearman rank-order correlation coefﬁcient (r) is 0.27 (95%
CI: 0.16, 0.38), and it is statistically signiﬁcantly different from 0
(two-sided p value of the test of r =0i s<0.0001).
FIGURE 3 | Structure based design and synthesis of MLCP inhibitors. (A)
17e docked into the crystal structure of PP1C showing the guanidine group
interacting with the hydrophobic groove and the dansyl portion of the
molecule interacting with the β12–13 loop. (B) Synthesis of MLCP inhibitors.
important for substrate recognition (Goldberg et al., 1995; Mills
et al., 1998; Maynes et al., 2001; Kita et al., 2002). We began an
in silico design of MLCP inhibitors using PP1C structural data,
based on the protein–ligand interactions of the oxazole moiety in
calyculin, a potent inhibitor for MLCP. We proposed several mol-
eculesfordocking(14a–jFigure3B)baseduponaseriesof amino
thiazolesthathadbeenpreviouslysynthesizedbyourgroup.These
compoundsappearedtoshowpromisinginteractionswiththecat-
alyticpocketof PP1C(Figure3A).Analysisof theﬂexibledocking
resultssuggestedtwopossiblebindingmodesforthisclassof com-
pounds. The main binding conformation involved the carbonyl
oxygen(s)ofthelinkergroupinteractingwiththebimetalliccenter
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of thecatalyticsite,leavingthehydrophobictailof themoleculeto
interactwiththeβ12–13loopofPP1C(Figure3A).Theguanidino
head group of the molecule formed a potential hydrogen bond
network with a backbone portion of the hydrophobic groove of
the protein. When the linker group of the docked molecule was
an amide, the main binding mode of this set of compounds was
reversed so that the guanidino head group interacted with the
metalcenterandthehydrophobictaildockedintothehydrophobic
groove of the protein.
Next, we focused our design efforts on two main structures
of the catalytic pocket, the hydrophobic groove and the β12–13
loop (Figure 3A). The β12–13 loop is a critical portion of the
catalytic pocket because it is highly ﬂexible and is the least con-
served portion of the binding pocket among the members of the
PPP superfamily. This loop and the hydrophobic groove together
are responsible for determining the substrate speciﬁcity imparted
onto the catalytic subunit by the regulatory subunit MYPT1 and
is important to inhibitor binding. This led us to expand the
hydrophobic region of the inhibitor molecule through an ester
linkage. This modiﬁcation resulted in modest MLCP inhibition
(13m, 840 and 14a, 485μM). We continued our optimization by
addingaguanidinothiazoletothisseriesofcompoundsandfound
theinhibitoryeffectwaspronouncedlyincreased,asincompound
13a (74μM). With this active core structure in hand, we set out
todesignaseriesof guanidinethiazolesthatwouldhaveenhanced
inhibition of MLCP.
SYNTHESIS OF MLCP INHIBITORS
Theﬁrstseriesofcompoundssynthesizedwerehydrophobicmod-
iﬁcations of the ester linkage (compounds 10a,b, 13a,b,d,f,I and
14a,b,d,f,I; Figure 2). The commercially available benzoylchlo-
ride derivatives were reacted with either 4-aminoacetophenone or
4-hydroxyacetonephenone to yield the ester/amide linked
products 11a–j. These were brominated and condensed with
thioureas to produce the amino thiazole derivatives 14a–j. Addi-
tionof 2-imino-4-thiobiuretyieldedtheguanidinothiazolederiv-
atives13a–j.Thesecondsetofmodiﬁcationsinvolvedthebiphenyl
substitution pattern. We began by coupling the commercially
available boronic acid with 4-iodoacetophenone to yield the
biphenyl acids 7a and 7b. These acids were converted to the acid
chloridebytreatmentwiththionylchloride,andtheproductswere
esteriﬁed under basic conditions with 4-hydroxyacetophenone
to yield the linked acetophenones 8a and 8b. These ketones
were brominated alpha to the ketone and then condensed with
2-imino-4-thiobiuret to yield the guanidine thiazole products
10a and 10b. We found that the guanidino functionality on
the thiazole ring was critical to the potency of the compounds
(13a,7 4±16 versus 14a 485±164μM; Figure 4A). Molecular
modeling of the previously synthesized compounds suggested a
putative binding mode in which the electron rich carbonyl oxy-
gen of the linker directly interacted with the bimetallic center
of the catalytic pocket. We proposed a sulfonic ester substitu-
tion to provide enhanced electron density, facilitating increased
interaction with the metal center of the protein. In addition,
common groups like dansyl could be added, since its ﬂuores-
cent properties should permit ready monitoring of intracel-
lular delivery. These derivatives were synthesized by coupling
the commercially available sulfonyl chloride compounds to 4-
hydroxyacetophenone to form the coupled ketones 15a–e.T h e
ketones were then brominated and condensed with 2-imino-
4-thiobiuret to yield the guanidino thiazole products 17a–e.
When docked into PP1C, 17e adopted the conformation that
placed the guanidino portion of the molecule in a position
to form hydrogen bonds with the backbone carbonyl of Arg
FIGURE 4 | Inhibition of puriﬁed MLCP . (A) MLCP inhibition of
compounds from Figure 3B. Assay was performed with
32P-MLC as a
substrate. (B) Representative MLCP inhibition graph showing
2-imino-4-thiobiuret as a guanidine group control compound to 17e and
10a. Error is represented as SEM. (C) PC-3 cells treated with 17e
(yellow) for 60min co-stained with DAPI nuclear stain (blue). (D) PC-3
cells treated with 17e (yellow) with no DAPI showing that 17e does not
enter the nucleus.
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221 in the hydrophobic groove and the dansyl portion of the
molecule aligned in the β12–13 loop region of the catalytic pocket
(Figure 3A).
INHIBITION OF MLCP
The inhibitory potency of the thiazole compounds was examined
by puriﬁed MLCP from pig aorta smooth muscle using 32P-MLC
asthesubstrate.Figure4isrepresentativeoftheinhibitioncurveof
MLCP activity.A summary of the synthesized compounds’MCLP
IC50 values is tabulated in Figure 4A. 2-imino-4-thiobiuret did
not inhibit MLCP activity at 10mM (Figure 4B), demonstrating
that the guanidine group alone is not sufﬁcient to produce inhibi-
tion. The inhibitory potency depended on the molecule having an
extendedhydrophobicregionalongwiththeguanidineadditionto
theexocyclicamineof thethiazole.Therewasnosigniﬁcantdiffer-
enceinMLCPinhibitionbetweentheester,amide,orsulfonicester
activities, suggesting that electron rich carbonyl oxygen is all that
is required at this position. The IC50 value of the MLCP inhibitors
was improved from 840μM( 13m)t o1 2μM( 10a) through our
initial optimization efforts. Although compounds 10a and 13h
showed the greatest inhibition, they had much lower solubility
than 17e. One key property of our MLCP inhibitor 17e is that it
is ﬂuorescent and has higher solubility. Fluorescence microscopy
shows entry into cells as early as 60min after 17e exposure. 17e
localized predominately into the cytosolic compartment of the
cells (Figures 4C,D).
EFFECTS OF 17e ON THE GROWTH OF PROSTATE CANCER CELLS
To determine the effects 17e on prostate cancer growth, various
cancer cell lines were treated with either 17e or DMSO (0.001%)
vehiclefor48h.Thesecelllinesrepresentaprogressionof prostate
cancer from lower metastatic potential and androgen dependence
(LNCaP) to highly aggressive metastatic and CRPC cells (PC-3).
The GI50 for LNCaP cells was signiﬁcantly less sensitive to 17e
treatment, having a GI50 of ∼2μM( Figure 5A) compared to the
CRPC cell lines which showed GI50s of about 0.5μM. CRPC cell
lines (CWR22Rv1, DU145, and PC-3) show more inhibition of
c e l l sg r o w t ha f t e r17e treatment having a four-fold lower GI50 as
compared to AD prostate cells.
We performed BrdU incorporation studies on the AD and
independent prostate cell lines. Similarly to the growth inhibition
experiment differences in the sensitivity to 17e induced reduction
inDNAsynthesiswereobservedinthevariouscelllines.DNAsyn-
thesis was unaffected by 17e treatment at 1μM in LNCaP cells.
In contrast, BrdU incorporation decreased, comparing the pro-
gression models CWR22RV1 (∼70%),DU145 (∼40%),and PC-3
(∼10%) cells (Figure 5B). The BrdU results conﬁrm our results
with the GI50 assay showing an increased sensitivity of CRPC cells
to 17e.
EFFECTS OF 17e ON PROSTATE CANCER CELLS
Since the BrdU uptake assay showed a reduction in DNA synthe-
sis, we wanted to elucidate the point in the cell cycle phase that
was being disrupted. Cells treated with 17e (1μM) and submitted
for cell cycle analysis by FACS (Figure5C).After 6h of treatment,
17e caused an increased S and G2/M populations. Treatment for
24h caused complete cell cycle arrest in the G2/M phase of the
cell cycle which continued unchanged through 48h of treatment.
FACSanalysisalsoshowedanincreaseincellsdeath,asrepresented
bySubG1population,of treatedcellsafter48h(Figure5C).These
cellcycleeffectswerealsoreﬂectedinchangesincellularmorphol-
ogy in that PC-3 cells became more spherical and began showing
signiﬁcant numbers detached from the plate after 24h treatment
with 17e (1μM; data not shown).
FIGURE5|( A )GI50 for prostate cells treated with 17e 48h. Error represented
as SEM, n=5. (B) BrdU uptake of cells treated with 1μM 17e for 24h
compared to control. Error is represented as SEM, n=3. (C) Cell cycle
analysis of prostate cancer cells treated with 17e. CWR22RV1 and PC-3 cells
demonstrate G2/M arrest after 24h of 17e treatment while LNCaP cells show
little change from control. Error is represented as SEM, n=3.
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To investigate the differential action of 17e on LNCaP and PC-
3 cells, we analyzed the compound’s effect on the cytoskeletal
structure of each cell type. PC-3 and LNCaP cells were treated
atconcentrationsof 17e from250nMto5μM(500nMand3μM
concentrations not shown) for 2h and then were stained with
ﬂuorescently labeled phalloidin to visualize any F-actin disrup-
tion in the cells. Actin ﬁlaments stained with phalloidin–Alexa
Fluor 688 were disrupted in cells treated with 17e compared
to control cells (Figure 6). The actin disruption in PC-3 cells
begins at 250nM with the number of cells presenting the phe-
notype steadily increasing to 5μM. By contrast, LNCaP cells
did not show any disruption of the F-actin network up to the
highest dose. MLCP is a known regulator of actin reorganiza-
tion within cells, thus disregulation of actin ﬁlaments is a strong
marker of MLCP inhibition. This phenotype is consistent with
the disruption of microﬁlaments induced by ectopic expression
of CPI-17, a speciﬁc protein inhibitor for MLCP (Eto et al.,
2000).
AdecreaseinMLCPfunctioncausesadirectlossof cellmotility
bysiRNAexperiments(Xiaetal.,2005).Aswehaveseendisruption
in the F-actin portion of the cytoskeleton in PC-3 cells,we wished
to investigate whether this also caused a reduction in cell migra-
tion. To assess whether 17e disrupts cell migration,we performed
a Boyden chamber experiment on PC-3 cells using Insulin-like
growth factor 1 as the chemo-attractant for PC-3 cells. The cells
were plated on top of the membrane in serum free media plus
increasing drug concentrations. The bottom half of the chamber
contained IGF-1 and the appropriate 17e concentration. In the
presence of IGF-1, 17e caused a dose dependent decrease in the
migration of PC-3 cells through the membrane when compared
tothecontrolwellscontainingonlyIGF-1(Figure7).At3μMthe
migration was reduced to the same level as wells that contained
only serum free media showing complete disruption in the ability
of the PC-3 cells to migrate across the membrane. When com-
pared with the control wells,three times fewer cells were found in
the wells treated with 5μM 17e than with the chemo-attractant
IGF-1 alone.
To conﬁrm that 17e binding was speciﬁc phosphatase binding,
weusedprostatetissuestainingof thecompoundtodeterminethe
amountof drugdisplacedbytheknownMLCPinhibitorcalyculin
A. Serial sections of prostate tissue were taken and the ﬁrst was
stainedwith17e(10μM)andimagedforthelevelof ﬂuorescence.
The second of the serial sections was pretreated with the known
MLCP inhibitor calyculinA (1μM) followed by staining with 17e
and then imaged to determine the level of ﬂuorescence due to
bound 17e. Calyculin A pretreatment of the prostate tissue slice
caused a 60% reduction in ﬂuorescence intensity of the sample
due to 17e (Figure 8).
FIGURE 7 | PC-3 cells were used in a chemotaxis experiment to
measure cell migration.The absorbance represents the amount of stained
cells that migrated through the 8-μm membrane using insulin-like growth
factor 1 as the attractant. Error is represented as SEM, n=5.
FIGURE 6 | Disruption of actin cytoskeleton by a 2-h 17e treatment. PC-3
cells treated with 250nM, 1μM, and 5μM concentrations of 17e showing
increasing amounts of actin disruption when compared to control. Cells
presenting strong actin disruption or blebbing are highlighted by arrows.
LNCaP cells treated with 250nM, 1μM, and 5μM concentrations of 17e
showing no actin disruption when compared to control.
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FIGURE 8 | CalyculinA treatment causes a reduction in 17e binding to
human prostate cancer tissue. Serial sections of human prostate tissue
were stained with (A) 17e (10μM) for 1h and (B) pretreated with calyculin
A( 1μM) for 10min followed by 17e (10μM) for 1h. Random regions of the
tissue from each section were imaged for the average ﬂuorescence
intensity of 17e (C) showing that calyculin A causes a 60% reduction in 17e
binding (p <0.0005). Error is represented by SEM, n=4.
DISCUSSION
We have found that as prostate cancer cell lines become more
aggressive in growth, the level of the constituent proteins that
make up MLCP increases signiﬁcantly. This trend found in our
cell line progression model was found to also be present in tis-
sues from human prostate cancer patients. The most aggressive
prostate cancers with a Gleason’s score of 8–10 presented high
levels of MYPT1 owing to the increased presence of MLCP. The
cellularneedforthisincreasedproteinexpressioncouldbedirectly
linked to the prostate cancer cells very rapid rate of growth and
division.
We developed a series of compounds from a novel chemical
class that inhibit MLCP. Our lead compound in this series showed
very promising anti-proliferative effects in prostate cancer cells
and showed increased activity against CRPC versus AD prostate
cancer cell lines. Our MLCP inhibitor 17e causes several effects
on PC-3 cells which lend it to being a promising therapeutic
compound in addition to its sub-micromolar growth inhibition.
It causes a 10-fold reduction in DNA synthesis as measured by
BrdU uptake in CRPC PC-3 prostate cancer cells. A reduction
in DNA synthesis gives more credence to our belief that this is
not a purely cytotoxic mechanism of growth inhibition. 17e treat-
ment also causes G2/M cell cycle arrest. The G2/M phase is the
most sensitive portion of the cell cycle, so cells that are arrested
through treatment of 17e could potentially be sensitized to other
chemotherapeutic agents. We visualized a differential ability of
17e to disrupt the F-actin networks of PC-3 versus LNCaP cells.
PC-3 cells began showing disruption in their F-actin after a 2-h
treatment of 250nM whereas LNCaP cells did not demonstrate
any F-actin disruption at 20-fold higher dosage of 5μM. This
supports our hypothesis that the growth of the CRPC cell lines
is being reduced by a different mechanism than the AD LNCaP
cells. Compound 17e’s activity compares well to the levels of
MLCP present in the cell line, although the IC50 value of 17e
was 16 times higher than GI50 values. The substrate enzymatic
property of the puriﬁed MLCP consisting of the truncated 60-
kDa MYPT1 fragment and PP1 is identical to the intact enzyme
(Hirano et al., 1997), it is possible that the puriﬁed enzyme is
less sensitive to 17e, compared with the cellular MLCP. It is also
possible that a partial inhibition of cellular MLCP is sufﬁcient
to block the cell growth. MLCP is highly regulated through the
phosphorylation of MYPT1 subunit and other signals. Sponta-
neous MYPT1 phosphorylation has been found in cells (Kitazawa
et al., 2002). Thus, it is possible that the inhibitory phosphory-
lation level or other unknown factors are involved in the cellular
MLCP activity and the sensitivity to the compounds. However,
the ability of calyculin A to prevent the binding of 17e to human
prostate tissue samples, as seen through the reduction in ﬂuo-
rescence, lends more evidence that MLCP is indeed the target of
our compound. While this displacement assay does not speciﬁ-
cally identify MLCP as the binding partner for 17e as calyculin A
does not speciﬁcally inhibit MLCP, it helps to eliminate the pos-
sibility of a non-phosphatase involved mechanism of action for
compound 17e.
The ability of prostate cancer cells to migrate from their orig-
inal organ to other parts of the body is the most life threatening
aspect of prostate cancer. Non-metastatic prostate cancers can be
extremely slow growing and may never cause symptoms in the
patient before his death. Watchful waiting is a valid clinical treat-
ment of certain types of prostate cancer because the issues asso-
ciated with current prostate cancer treatments may outweigh the
dangers of a slow growing,non-metastatic prostate tumor. Unfor-
tunately, when CRPC phenotypes of prostate cancer emerge, the
median survival time is 23–37months. Reduction in median sur-
vival time is generally linked to metastasis; our MLCP inhibitor’s
ability to reduce the chemotaxis of PC-3 cells is of signiﬁcant
clinical importance.
In conclusion, we have developed an inhibitor of MLCP that
shows very potent growth inhibition of CRPC prostate cancer
cells. Importantly, cells with higher levels of MLCP demon-
strate increased sensitivity to 17e treatment over cells with lower
expression levels which would potentially allow 17e to target
aggressive cancerous portions of the prostate over benign areas
of tissue, thereby reducing the possibility of toxicity. This com-
pound also possesses ﬂuorescent properties that allow its entry
into the cell to be tracked and could possibly be used as a diagnos-
tic tool in tissues. With a potentially non-cytotoxic mechanism,
as suggested by the reduction in DNA synthesis, and the abil-
ity to arrest cells in the G2/M phase of the cells cycle, this new
class of compounds has the potential to become an important
therapeutic agent in the treatment of metastatic CRPC prostate
cancer.
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APPENDIX
CHEMICAL SYNTHESIS
Synthesis of 3-methoxy-biphenyl-4-carboxylic acid (7a)
A solution of 3-methoxyphenyl boronic acid (1g, 6.58mmol),
4-iodobenzoic acid (1.63g, 6.58mmol) and Cs2CO3 (5.36g,
16.45mmol) in 3:1 DME/H2O was degassed with nitrogen for
15min. Pd(PPh3)4 (380mg,0.329mmol) was then added and the
solution was heated to 80˚C for 6h. The reaction was allowed to
coolandacidiﬁedwith2MHClwhichcausedaprecipitatetoform.
The precipitate was ﬁltered and the ﬁltrate was extracted twice
with DCM. The organic layer was then dried over MgSO4,ﬁltered
throughCelite,andevaporatedtoawhitesolidwhichwaspuriﬁed
via column choromatography (4:1 Hex/EtOAc w/ 1% HOAc) and
was combined with the precipitate to yield 1.04g (69%). 1HNMR
(DMSO):δ8.01(d,J =8.1Hz,2H),7.80(d,J =8.1Hz,2H),7.41
(t, J =7.8Hz, 1H), 7.30–7.25 (m, 3H), 6.99 (d, J =8.1Hz, 1H),
3.83 (s, 3H). MS, ESI, m/e 229 (MH+).
Synthesis of 4-methoxy-biphenyl-4-carboxylic acid (7b)
Method A. Coumalic acid (1.06g, 7.56mmol) and 4-ethylnyl
anisole were dissolved in diglyme and brought to reﬂux for
36h. The reaction was then allowed to cool and the solvent was
removed under reduced pressure. The resultant slurry was then
recrystallized in EtOH to yield 754mg (44%) of a light tan solid.
Method B. A solution of 4-methoxyphenyl boronic acid (1g,
6.58mmol), 4-iodobenzoic acid (1.63g, 6.58mmol) and Cs2CO3
(5.36g,16.45mmol)in3:1DME/H2Owasdegassedwithnitrogen
for 15min. Pd(PPh3)4 (380mg,0.329mmol) was then added and
thesolutionwasheatedto80˚Cfor6h.Thereactionwasallowedto
coolandacidiﬁedwith2MHClwhichcausedaprecipitatetoform.
The precipitate was ﬁltered and the ﬁltrate was extracted twice
with DCM. The organic layer was then dried over MgSO4,ﬁltered
through Celite,and evaporated to yield a combined 1.50g (95%).
1HNMR (DMSO): δ 7.99 (d, J =8.4Hz, 2H), 7.74 (d, J =8.4Hz,
2H), 7.69 (d, J =8.7Hz, 2H), 7.04 (d, J =8.7Hz, 2H), 3.80 (s,
3H). 13CNMR (DMSO): δ 167.17,159.49,143.90,131.16,129.91,
128.77, 128.09, 126.08, 114.45, 55.17.
Synthesis of 3-methoxy-biphenyl-4-carboxylic acid
4-acetyl-phenyl ester (8a)
3 -Methoxy-biphenyl-4-carboxylic acid (500mg, 2.03mmol) was
dissolvedinthionylchloride(25mL)andallowedtostirovernight.
The thionyl chloride was then pumped off and the acid chloride
was carried on crude. The acid chloride was dissolved in DCM
and 4-hydroxyacetophenone (276mg, 2.03mmol) was added to
the solution. NaH (60% in mineral oil, 81mg, 2.03mmol) was
then added slowly to the reaction and allowed to stir for 5h. The
reaction was then quenched with sat. NaHCO3 and the solution
wasextractedtwicewithDCM.Thecombinedorganiclayerswere
then dried over MgSO4, ﬁltered, and evaporated to a solid which
was carried on crude. 1HNMR (DMSO): δ 8.21 (d, J =8.4Hz,
2H), 8.09 (d, J =8.7Hz, 2H), 7.94 (d, J =8.4Hz, 2H), 7.48 (d,
J =8.7Hz,2H),7.43(d,J =7.8Hz,1H),7.36–7.32(m,2H),7.03
(dd, J =7.2, 1.8Hz, 1H), 3.85 (s, 3H), 2.62 (s, 3H). 13CNMR
(DMSO): δ 196.88, 163.94, 159.77, 154.19, 145.36, 140.05, 134.55,
130.46, 130.19, 129.88, 127.42, 127.23, 122.20, 119.30, 114.21,
112.42, 55.17, 26.74.
Synthesis of 4-methoxy-biphenyl-4-carboxylic acid
4-acetyl-phenyl ester (8b)
4 -Methoxy-biphenyl-4-carboxylic acid (400mg, 1.60mmol) was
dissolvedinthionylchloride(25mL)andallowedtostirovernight.
The thionyl chloride was then pumped off and the acid chloride
was carried on crude. The acid chloride was dissolved in DCM
and 4-hydroxyacetophenone (218mg, 1.60mmol) was added to
the solution. NaH (60% in mineral oil, 64mg, 1.60mmol) was
then added slowly to the reaction and allowed to stir for 5h. The
reaction was then quenched with sat. NaHCO3 and the solution
wasextractedtwicewithDCM.Thecombinedorganiclayerswere
then dried over MgSO4, ﬁltered, and evaporated to a solid which
was carried on crude. 1HNMR (DMSO): δ 8.18 (d, J =5.1Hz,
2H), 8.08 (d, J =5.1Hz, 2H), 7.88 (d, J =5.1Hz, 2H), 7.76 (d,
J =5.1Hz,2H),7.48(d,J =5.1Hz,2H),7.08(d,J =5.1Hz,2H),
3.82 (s, 3H), 2.62 (s, 3H).
Synthesis of 3-methoxy-biphenyl-4-carboxylic acid
4-(2-bromo-acetyl)-phenyl ester (9a)
Bromine (226mg, 1.66mmol) was added dropwise to a solution
of 3 -Methoxy-biphenyl-4-carboxylic acid 4-acetyl-phenyl ester
(577mg,1.66mmol) in HOAc as per the general procedure which
yielded 700mg (99%). 1HNMR (DMSO): δ 8.22 (d, J =8.4Hz,
2H), 8.13 (d, J =8.7Hz, 2H), 7.94 (d, J =8.4Hz, 2H), 7.53 (d,
J =8.4Hz, 2H), 7.45 (t, J =7.8Hz, 1H), 7.34 (m, 2H), 7.03 (dd,
J =7.5, 2.1Hz, 1H).
Synthesis of 3-methoxy-biphenyl-4-carboxylic acid
4-(2-guanidino-thiazol-4-yl)-phenyl ester, HBr salt (10a)
2-Imino-4-thiobiuret (186mg, 1.57mmol) was added to a
solution of 3 -Methoxy-biphenyl-4-carboxylic acid 4-(2-bromo-
acetyl)-phenylester(669mg,1.57mmol)inacetoneasperthegen-
eral procedure which yielded 490mg (56%). 1HNMR (DMSO): δ
8.19(m,6H),8.05(d,J =8.5Hz,2H),7.92(d,J =7Hz,1H),7.80
(s, 1H), 7.68–7.62 (m, 1H), 7.43 (t, J =8Hz, 1H), 7.39 (m, 2H),
7.33 (d,J =8Hz,1H),7.29 (s,1H),7.04–6.96 (m,1H). 13CNMR
(DMSO): δ 164.27, 159.77, 153.84, 150.47, 145.21, 140.07, 133.84,
130.93, 130.38, 130.19, 129.80, 129.61, 127.16, 122.24, 119.28,
116.58, 114.15, 112.42, 108.20.
Synthesis of 4-methoxy-biphenyl-4-carboxylic acid
4-(2-guanidino-thiazol-4-yl)-phenyl ester, HBr salt (10b)
Bromine (125mg, 0.78mmol) was added to a solution
of 4 -Methoxy-biphenyl-4-carboxylic acid 4-acetyl-phenyl ester
(266mg, 0.78mmol) in HOAc as per the general-bromo proce-
dure which yielded 285mg (86%) which was carried on crude.
The ketone (280, 0.66mg) and 2-imino-4-thiobiuret (78mg,
0.66mmol)werecombinedinacetoneandbroughttoreﬂuxasper
the general procedure yielding 136mg (40%). 1HNMR (DMSO):
δ 8.18 (d, J =8.1Hz, 2H), 8.00 (d, J =8.4Hz, 2H), 7.87 (d,
J =8.1Hz,2H),7.74 (d,J =8.7Hz,2H),7.53 (s,br,4H),7.35 (d,
J =8.4Hz, 2H), 7.08 (d, J =8.7Hz, 2H), 3.82 (s, 3H). 13CNMR
(DMSO): δ 164.36, 159.74, 155.25, 150.12, 148.71, 144.95, 131.69,
130.75, 130.44, 128.21, 126.85, 126.33, 122.13, 114.52, 105.92,
55.22.
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Synthesis of biphenyl-4-carboxylic acid 4-acetyl-phenyl ester (11a)
4-Hydroxyacetophenone (1g, 7.35mmol) was added to a slurry
of NaH (60% in mineral oil, 294mg, 7.35mmol) in THF and was
allowed to stir for 10min. 4-biphenylcarbonyl chloride (1.59g,
7.35mmol) was then added to this mixture dropwise and allowed
to stir for 5h. The reaction was quenched with water and the
precipitate was ﬁltered and dried in a dessicator. The aqueous
layerwasthenextractedthreetimeswithEtOAc.Theorganiclayer
was dried over MgSO4, ﬁltered, and evaporated to yield 2.08g
(89%) of a white solid. 1HNMR (DMSO): δ 8.22 (d, J =6.9Hz,
2H), 8.08 (d, J =7.2Hz, 2H), 7.93 (d, J =6.1Hz, 2H), 7.78 (d,
J =6Hz, 2H), 7.49 (m, 5H), 2.61 (s, 3H). 13CNMR (CDCl3):
δ 164.75, 154.94, 146.90, 135.03, 131.01, 130.24, 129.23, 128.64,
127.90,127.54,122.17,31.164,26.86. MS,APCI,m/e 317 (MH+).
Synthesis of 4-tert-butyl-benzoic acid 4-acetyl-phenyl ester (11b)
4-Hydroxyacetophenone (691mg, 5.08mmol) was added to a
slurry of NaH (60% in mineral oil, 244mg, 6.10mmol) in THF
and was allowed to stir for 10min. 4-tert-butyl benzoyl chlo-
ride (1g, 5.08mmol) was then added to this mixture dropwise
and allowed to stir for 5h. The reaction was then quenched with
water and extracted three times with EtOAc. The organic layer
was dried over MgSO4, ﬁltered, and evaporated to yield 1.36g
(90%) of a white solid. 1HNMR (CDCl3): δ 8.13 (d, J =8.7Hz,
2H), 8.05 (d, J =8.7Hz, 2H), 7.54 (d, J =8.7Hz, 2H), 7.32 (d,
J =8.4Hz, 2H), 2.63 (s, 3H), 1.37 (s, 9H). 13CNMR (CDCl3):
δ 197.25, 164.85, 158.04, 155.02, 134.86, 130.38, 130.21, 126.37,
125.88, 122.19, 35.45, 31.28, 26.85. MS,APCI, m/e 297 (MH+).
Synthesis of N-(4-acetyl-phenyl)-4-tert-butyl-benzamide (11c)
4 -tert-Butylbenzoyl chloride was added dropwise to a solution
of 4-aminoacetophenone and TEA (2mL) in EtOAc. The solu-
tion was allowed to stir for 4h, was quenched with water and
extracted with EtOAc three times. The organic layers were then
dried over MgSO4, ﬁltered, and evaporated to yield 1.56g (71%)
of theamide. 1HNMR(DMSO):δ7.965(d,J =2.7Hz,4H),7.907
(d,J =8.4Hz,2H),7.560(d,J =8.4Hz,2H),2.547(s,3H),1.322
(s, 9H).
Synthesis of 4-n-butyl-benzoic acid 4-acetyl-phenyl ester (11d)
4-Hydroxyacetophenone (691mg, 5.08mmol) was added to a
slurry of NaH (60% in mineral oil, 244mg, 6.10mmol) in THF
andwasallowedtostirfor10min.4-n-butylbenzoylchloride(1g,
5.08mmol) was then added to this mixture dropwise and allowed
to stir for 5h. The reaction was then quenched with water and
extracted three times with EtOAc. The organic layer was dried
over MgSO4, ﬁltered, and evaporated to yield 1.36g (90%) of a
white solid. 1HNMR (CDCl3): δ 8.11 (d, J =8.1Hz, 2H), 8.04
(d, J =8.7Hz, 2H), 7.34 (d, J =1.8Hz, 2H), 7.31 (d, J =2.1Hz,
2H),2.71 (t,J =7.5Hz,2H),2.62 (s,3H),1.64 (quin,J =7.4Hz,
2H),1.37(sext,J =7.5Hz,2H),0.95(t,J =7.2Hz,3H).13CNMR
(CDCl3): δ 197.26, 164.91, 155.00, 149.99, 134.84, 131.08, 130.53,
130.20, 128.97, 126.58, 122.18, 115.51, 35.99, 33.43, 26.84, 22.50,
14.10. MS,APCI, m/e 297 (MH+).
Synthesis of N-(4-acetyl-phenyl)-4-butyl-benzamide (11e)
4-Butylbenzoyl chloride was added dropwise to a solution of 4-
aminoacetophenone and TEA (2mL) in EtOAc. The solution was
allowed to stir for 4h, was quenched with water and extracted
with EtOAc three times. The organic layers were then dried over
MgSO4,ﬁltered,andevaporatedtoyield1.56g(71%)oftheamide.
1HNMR (DMSO): δ 7.959 (m, 4H), 7.897 (d, J =8.1Hz, 2H),
7.358 (d,J =8.1Hz,2H),2.658 (t,J =7.8Hz,2H),2.546 (s,3H),
1.583 (sextup, J =7.2Hz, 2H), 1.323 (sextup, J =7.5Hz, 2H),
0.900 (t,J =7.5Hz, 3H).
Synthesis of 4-cyclopropyl-benzoic acid
Coulmalic acid (2.63g, 18.74mmol) and ethynylcyclopropane
(1.24g, 18.74mmol) were combined in diglyme and brought to
reﬂux for 36h. The reaction was then cooled and the solvent was
removed under reduced pressure. The resultant slurry was recrys-
tallized in EtOH to yield 1.26g (42%). 1HNMR (DMSO): δ 7.81
(d,J =8.4Hz,2H),7.16(d,J =8.4Hz,2H),1.97(sept,J =5.1Hz,
1H), 1.01 (m, 2H), 0.74 (m, 2H). 13CNMR (DMSO): δ 167.24,
149.51, 129.32, 127.65, 125.19, 15.25, 10.37.
Synthesis of 4-cyclopropyl-benzoic acid 4-acetyl-phenyl ester (11f)
Oxalyl chloride(2.92g,22.2mmol) was added dropwise to a solu-
tion of 4-cyclopropyl-benzoic acid (1.20g, 7.4mmol) in DCM.
The solution was allowed to stir overnight and the solvent was
removed under reduced pressure. The acid chloride was then
carried on crude. 4-hydroxyacetophenone (1.01g, 7.4mmol) was
added to a slurry of NaH (60% in mineral oil, 296mg, 7.4mmol)
in DCM and allowed to stir for 10min. 4-cyclopropyl-benzoyl
chloride (1.33g, 7.4mmol) was then added and the solution was
allowed to stir for 3h. The reaction was then quenched with water
and extracted three times with DCM. The combined organic
layers were then dried over MgSO4, ﬁltered, and evaporated to
yield 1.83g (88% over two steps). 1HNMR (CDCl3): δ 8.07 (t,
J =8.7Hz,4H),7.31(d,J =8.4Hz,2H),7.17(d,J =8.4Hz,2H),
2.62 (s, 3H), 1.98 (sept, J =5.1Hz, 1H), 1.10 (m, 2H), 0.82 (m,
2H). 13CNMR (CDCl3): δ 196.91, 164.60, 154.77, 151.36, 134.61,
130.30, 129.94, 125.91, 125.55, 121.95, 26.62, 15.85, 10.61.
Synthesis of naphthalene-2-carboxylic acid
(4-acetyl-phenyl)-amide (11h)
2-Naphthoyl chloride (1g,5.25mmol) was added to a solution of
4-aminoacetophenone(710mg,5.25mmol)in1:1DCM/pyridine
and allowed to stir for 4h. The solvent was then removed under
reduced pressure and the oil was extracted with DCM and sat.
CuCO4. The combined organic layers were then washed with
water, dried over MgSO4, ﬁltered, and evaporated to yield 1.46g
(96%)ofawhitesolid. 1HNMR(DMSO):δ8.62(s,1H),8.12–8.09
(m, 1H), 8.06 (m, 2H), 8.01 (s, 5H), 7.68–7.61 (m, 2H), 2.56 (s,
3H). 13CNMR (DMSO): δ 196.53,165.96,143.62,134.32,131.94,
131.79, 129.29, 128.95, 128.22, 128.04, 127.94, 127.64, 126.87,
124.39, 119.38, 26.42.
Synthesis of naphthalene-2-carboxylic acid 4-acetyl-phenyl ester
(11i)
4-Hydroxyacetophenone (713mg, 5.24mmol) was added to a
slurry of NaH (60% in mineral oil, 210mg, 5.24mmol) in THF
and was allowed to stir for 10min. 2-Naphthoyl chloride (1g,
5.24mmol) was then added to this mixture dropwise and allowed
to stir for 5h. The reaction was then quenched with water and
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extracted three times with EtOAc. The organic layer was dried
over MgSO4, ﬁltered, and evaporated to yield 952mg (63%) of a
white solid. 1HNMR (DMSO): δ 8.88 (s, 1H), 8.22 (d, J =7.8Hz,
1H), 8.16–8.06 (m, 5H) 7.76–7.65 (m, 2H), 7.52 (d, J =8.7Hz,
2H), 2.63 (s, 3H). 13CNMR (DMSO): δ 197.65, 165.06, 155.03,
136.10, 135.31, 132.76, 132.45, 130.67, 130.26, 129.82, 129.37,
128.48, 127.92, 126.49, 125.72, 123.03, 27.50. MS, APCI, m/e 373
(MH+).
Synthesis of naphthalene-1-carboxylic acid
(4-acetyl-phenyl)-amide (11j)
1-Naphthoyl chloride (2g,10.5mmol) was added to a solution of
4-aminoacetophenone (1.42g, 10.5mmol) in 1:1 DCM/pyridine
and allowed to stir for 4h. The solvent was then removed under
reduced pressure and the oil was extracted with DCM and sat.
CuCO4. The combined organic layers were then washed with
water, dried over MgSO4, ﬁltered, and evaporated to yield 2.96g
(97%)of awhitesolid. 1HNMR(DMSO):δ8.19(m,1H),8.11(d,
J =8.1Hz, 1H), 8.00 (m, 5H), 7.81 (d, J =6.9Hz, 1H), 7.63 (m,
3H), 2.57 (s, 3H). 13CNMR (DMSO): δ 196.53, 167.62, 143.57,
134.15, 133.08, 132.00, 130.40, 129.49, 129.39, 128.33, 127.10,
126.39, 125.68, 124.94, 118.98, 26.44.
Bromination general procedure for the of ketones
The ketone was dissolved in CHCl3 and 1 equivalent of bromine
wasaddeddropwisetothesolution.Iftheketonewasnotsolublein
CHCl3, HOAc was used as the solvent. The reaction was allowed
to stir until the bromine color was discharged (3h-overnight).
For CHCl3, the reaction was then quenched with sat. NaHCO3
and was extracted three times with DCM. For HOAc, the solu-
tion was diluted with water and extracted three times with DCM.
The DCM extracts were then washed with sat. NaHCO3.T h e
organic layer was then dried over MgSO4, ﬁltered, and evapo-
rated to yield the α-bromo ketone which was carried on without
further puriﬁcation.
Synthesis of biphenyl-4-carboxylic acid 4-(2-bromo-acetyl)-phenyl
ester (12a)
Bromine (757mg, 4.74) was added dropwise to a solu-
tion of Biphenyl-4-carboxylic acid 4-acetyl-phenyl ester (1.5g,
4.74mmol) in HOAc as per the general procedure. The reac-
tion yielded 1.3g (70%). 1HNMR (DMSO): δ 8.23 (d, J =7.8Hz,
2H), 8.14 (d, J =8.1Hz, 2H), 7.93 (d, J =8.1Hz, 2H), 7.79 (d,
J =6.9Hz,2H),7.54–7.50 (m,5H). 13CNMR (DMSO):δ 190.64,
163.86, 154.63, 145.49, 138.52, 131.66, 130.49, 129.06, 128.55,
127.06, 122.40, 34.05.
Synthesis of 4-tert-butyl-benzoic acid 4-(2-bromo-acetyl)-phenyl
ester (12b)
Bromine (425mg, 2.66mmol) was added to a solution of 4-tert-
Butyl-benzoic acid 4-acetyl-phenyl ester (788mg, 2.66mmol) in
CHCl3 as per the general procedure. The reaction yielded 859mg
(86%) of the α-bromo ketone. 1HNMR (CDCl3): δ 8.12 (d,
J =8.4Hz,2H),8.07(d,J =8.7Hz,2H),7.54(d,J =8.4Hz,2H),
7.35 (d, J =8.7Hz, 2H), 4.45 (s, 2H), 1.37 (s, 9H). 13CNMR
(CDCl3): δ 190.39, 185.77, 158.17, 155.61, 131.78, 130.91, 130.42,
125.93, 122.54, 39.67, 35.48, 31.30, 30.89.
Synthesis of N-[4-(2-bromo-acetyl)-phenyl]-4-tert-butyl-benzamide
(12c)
Bromine (1.29g, 5.08mmol) was added to a solution of N-
(4-Acetyl-phenyl)-4-tert-butyl-benzamide (1.5g, 5.08mmol) in
CHCl3 as per the general procedure yielding 1.90g (99%).
1HNMR (CDCl3):δ 8.108 (d,J =7.5Hz,2H),7.82 (d,J =7.5Hz,
4H), 7.511 (d,J =7.5Hz, 2H), 6.693 (s, 1H), 1.351 (s, 9H).
Synthesis of 4-butyl-benzoic acid 4-(2-bromo-acetyl)-phenyl ester
(12d)
Bromine (471mg, 2.95mmol) was added to a solution of 4-n-
Butyl-benzoic acid 4-acetyl-phenyl ester (876mg, 2.95mmol) in
CHCl3 as per the general procedure. The reaction yielded 1.06g
(96%) of the α-bromo ketone. 1HNMR (CDCl3): δ 8.13–8.04
(m, 4H), 7.49–7.42 (m, 4H), 4.96 (t, J =1.5Hz, 2H), 2.69–2.68
(m, 2H), 1.59–1.57 (m, 2H), 1.32–1.28 (m, 2H), 0.92–0.87 (m,
3H). 13CNMR (CDCl3): δ 190.69, 164.08, 154.77, 149.50, 131.67,
130.56, 130.02, 129.90, 128.93, 122.48, 34.86, 34.12, 32.71, 21.70,
13.73.
Synthesis of N-[4-(2-bromo-acetyl)-phenyl]-4-butyl-benzamide (12e)
Bromine (1.099g, 6.88mmol) was added dropwise to a solution
of N-(4-Acetyl-phenyl)-4-butyl-benzamide (2.032g, 6.88mmol)
in methanol as per the general procedure to yield 2.43g
(94%). 1HNMR (DMSO): δ 7.876 (d, J =8.1Hz, 2H), 7.787 (d,
J =8.7Hz, 2H), 7.421 (d, J =8.7Hz, 2H), 7.347 (d, J =8.1Hz,
2H),3.801 (s,2H),2.657 (t,J =7.5Hz,2H),1.586 (p,J =7.2Hz,
2H), 1.314 (sextup, J =7.2Hz, 2H), 0.905 (t,J =7.2Hz, 3H).
Synthesis of 4-cyclopropyl-benzoic acid 4-(2-bromo-acetyl)-phenyl
ester (12f)
Bromine (1.04g, 6.53mmol) was added dropwise to a solu-
tion of 4-cyclopropyl-benzoic acid 4-acetyl-phenyl ester (1.83g,
6.53mmol) in CHCl3 as per the general procedure which yielded
2.32g(99%). 1HNMR(CDCl3):δ8.07(d,J =8.7Hz,4H),7.35(d,
J =8.7Hz,2H),7.17 (d,J =8.4Hz,2H),4.45 (s,2H),1.99 (sept,
J =4.8Hz, 1H), 1.10 (m, 2H), 0.82 (m, 2H). 13CNMR (CDCl3):
δ 190.10, 164.44, 155.38, 151.51, 131.36, 130.64, 130.33, 129.94,
125.58, 122.28, 121.64, 30.69, 15.85, 10.62.
Synthesis of naphthalene-2-carboxylic acid
[4-(2-bromo-acetyl)-phenyl]-amide (12h)
Bromine (123mg, 0.773mmol) was added dropwise to a solu-
tion of Naphthalene-2-carboxylic acid (4-acetyl-phenyl)-amide
(224mg,0.773mmol) in HOAc as per the general procedure. The
α-bromoketone was carried on without further puriﬁcation or
characterization.
Synthesis of naphthalene-2-carboxylic acid
4-(2-bromo-acetyl)-phenyl ester (12i)
Bromine (511mg, 3.19) was added dropwise to a solution of
Naphthalene-2-carboxylic acid 4-acetyl-phenyl ester (928mg,
3.19mmol) in HOAc as per the general procedure. The α-
bromoketone was carried on without further puriﬁcation or
characterization.
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Synthesis of naphthalene-1-carboxylic acid
[4-(2-bromo-acetyl)-phenyl]-amide (12j)
Bromine (552mg, 3.46mmol) was added dropwise to a solu-
tion of Naphthalene-1-carboxylic acid (4-acetyl-phenyl)-amide
(1g, 3.46mmol) in CHCl3 as per the general procedure to yield
1.18g (93%). 1HNMR (DMSO): δ 8.20–8.17 (m, 1H), 8.11 (d,
J =8.1Hz,1H),8.07–7.97(m,5H),7.81(d,J =6.6Hz,1H),7.63
(m, 3H), 4.90 (s, 2H).
Synthesis of 2-bromo-1-(4-methoxy-phenyl)-ethanone (12m)
Bromine (1.06g, 6.67mmol) was added dropwise to a solution
of 4-methoxyacetophenone (1g, 6.67mmol) in CHCl3 as per the
general procedure to yield 1.35g (88%). 1HNMR (CDCl3): δ 7.97
(d, J =9Hz, 2H), 6.95 (d, J =9Hz, 2H), 4.40 (s, 2H), 3.88 (s,
3H). 13CNMR (CDCl3): δ 189.92, 164.09, 131.34, 126.85, 114.03,
55.55, 30.71.
General synthesis of 2-aminothiazoles from acetophenones
In this reaction, Eq. 1 of Acetophenone, Eq. 1 of Iodine and Eqs
2–4 of Thiourea were added to 20mL of ethanol and heated to
110˚C open to the atmosphere and allowed to stir for 3hours. The
ethanolwasreplacedasitevaporated.Theﬁnalportionof ethanol
wasallowedtoevaporatetodryness.Ifanoilwasformed,etherwas
added and then removed under reduced pressure to freeze the oil
toasolid.Thesolidwasthenwashedwithhotwateruntilthesolid
became ﬂoculant. The solid was then ﬁltered and washed three
times with ether. The solid was then dried in a vacuum desecator.
General procedure for the synthesis of guanidio thiazoles
A solution of α-bromoketone (Eq. 1) and 2-imino-4-thiobiuret
(Eq. 1) in acetone was brought to reﬂux for 3h during which a
precipitate formed. The reaction was allowed to cool; the product
was ﬁltered and washed with ether.
Synthesis of biphenyl-4-carboxylic acid
4-(2-guanidino-thiazol-4-yl)-phenyl ester, HBr salt (13a)
2-Imino-4-thiobiuret (695mg, 5.88mmol) was added to a solu-
tion Biphenyl-4-carboxylic acid 4-(2-bromo-acetyl)-phenyl ester
(1.3g, 3.30mmol) as per the general procedure yielding 1.25g
(76%). 1HNMR (DMSO): δ 8.25 (s, br, 4H), 8.22 (d, J =8.4Hz,
2H), 8.07 (d, J =8.7Hz, 2H), 7.92 (d, J =8.4Hz, 2H), 7.83 (s,
1H), 7.78 (d, J =7.2Hz, 2H), 7.53 (t, J =6.9Hz, 2H), 7.47 (d,
J =7.2Hz, 1H), 7.40 (d, J =8.7Hz, 2H). 13CNMR (DMSO):
δ 164.30, 159.95, 153.73, 150.52, 145.35, 138.59, 130.87, 130.48,
129.11,128.57,127.55,127.20,127.07,127.00,122.27,108.39. MS,
APCI, m/e 415 (MH+).
Synthesis of 4-tert-butyl-benzoic acid
4-(2-guanidino-thiazol-4-yl)-phenyl ester, HBr salt (13b)
2-Imino-4-thiobiuret (126mg, 1.065mmol) was added to a solu-
tionof 4-tert-Butyl-benzoicacid4-(2-bromo-acetyl)-phenylester
(400mg, 1.065mmol) as per the general procedure yielding
207mg (41%) of a white solid. 1HNMR (DMSO): δ 8.23 (s,
br, 4H), 8.08 (d, J =8.5Hz, 2H), 8.06 (d, J =9Hz, 2H), 7.83
(s, 1H), 7.65 (d, J =8Hz, 2H), 7.35 (d, J =9Hz, 2H), 1.33 (s,
9H). 13CNMR (DMSO): δ 164.36,159.97,157.24,153.71,150.52,
149.03, 130.81, 129.72, 127.15, 126.02, 125.76, 122.27, 108.35,
34.93, 30.72.
Synthesis of
4-tert-butyl-N-[4-(2-guanidino-thiazol-4-yl)-phenyl]-benzamide (13c)
2-Imino-4-thiobiuret (63.1mg,0.534mmol) was added to a solu-
tion of N-[4-(2-Bromo-acetyl)-phenyl]-4-tert-butyl-benzamide
(200mg, 0.534mmol) as per the general procedure yielding
79.2mg(31%). 1HNMR(DMSO):δ8.156(s,4H),7.916(m,6H),
7.654 (s, 1H), 7.343 (d, J =8.1Hz, 2H), 1.351 (s, 9H). 13CNMR
(DMSO): δ 170.386, 165.921, 161.012, 153.986, 149.724, 146.143,
139.219, 132.280, 128.303, 128.211, 127.824, 126.204, 120.121,
106.613, 34.717, 30.950.
Synthesis of 4-butyl-benzoic acid
4-(2-guanidino-thiazol-4-yl)-phenyl ester, HBr salt (13d)
2-Imino-4-thiobiuret (157mg, 1.33mmol) was added to a solu-
tion of 4-Butyl-benzoic acid 4-(2-bromo-acetyl)-phenyl ester
(500mg,1.33mmol)asperthegeneralprocedureyielding335mg
(53%) of a while solid. 1HNMR (DMSO): δ 8.156 (s, 4H), 8.04
(d, J =8Hz, 2H), 7.831 (d, J =8.8Hz, 2H), 7.419 (d, J =8.4Hz,
4H),7.277 (s,1H),2.681 (t,J =7.6Hz,2H),1.576 (p,J =7.6Hz,
2H), 1.298 (sextup, J =7.2Hz, 2H), 0.889 (t, J =7.2Hz, 3H).
13CNMR (DMSO):δ 170.121,164.339,151.160,149.310,138.795,
129.889, 128.874, 127.149, 126.762, 126.081, 122.593, 102.987,
34.779, 32.666, 21.644, 13.691.
Synthesis of
4-butyl-N-[4-(2-guanidino-thiazol-4-yl)-phenyl]-benzamide (13e)
2-Imino-4-thiobiuret(315.7mg,2.67mmol),wasaddedtoasolu-
tion of N-[4-(2-Bromo-acetyl)-phenyl]-4-butyl-benzamide (1g,
2.67mmol)in acetone as per the general procedure which yielded
577mg (46%). 1HNMR (DMSO):δ 8.156 (s,4H),7.916 (m,6H),
7.654 (s, 1H), 7.343 (d, J =8.1Hz, 2H), 2.65 (t, J =7.5, 2H),
1.577 (p,J =7.2Hz,2H),1.301 (sextup,J =7.5Hz,2H),0.895 (t,
J =7.5Hz, 3H). 13CNMR (DMSO): δ 170.224, 165.407, 160.801,
154.007, 149.551, 146.320, 139.288, 132.180, 128.323, 128.181,
127.679,126.207,120.117,106.534,59.663,34.586,32.803,21.634,
20.665, 13.994, 13.661.
Synthesis of 4-cyclopropyl-benzoic acid
4-(2-guanidino-thiazol-4-yl)-phenyl ester, HBr salt (13f)
2-Imino-4-thiobiuret (763mg, 6.46mmol), was added to a solu-
tion of 4-cyclopropyl-benzoic acid 4-(2-bromo-acetyl)-phenyl
ester (2.32g, 6.46mmol) in acetone as per the general proce-
dure which yielded 1.96g (66%). 1HNMR (DMSO): δ 8.26 (s,
br, 4H), 8.05 (d, J =8.7Hz, 2H), 8.00 (d, J =8.4Hz, 2H), 7.81
(s,1H),7.34 (d,J =8.7,2H),7.28 (d,J =8.4Hz,2H),2.05 (sept,
J =5.1Hz,1H),1.07 (m,2H),0.80 (m,2H). 13CNMR (DMSO):
δ 164.38, 159.89, 153.78, 151.13, 150.52, 149.03, 130.75, 129.83,
127.16, 125.56, 122.23, 108.33, 15.39, 10.68. MS, ESI, m/e 379
(MH+).
Synthesis of N-[4-(4-benzoyl-phenyl)-thiazol-2-yl]-guanidine, HBr
salt (13g)
A solution of 4-Benzoyl-benzoic acid (500mg, 2.21mmol) in
THF was cooled to −78˚C and 1.6M solution of MeLi (4.14mL,
6.63mmol) was added dropwise. The reaction was then allowed
tostirfor1hat −78˚Candthenanother3hatroomtemperature.
The reaction was then quenched by slowly adding sat. NaHCO3
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and extracted with EtOAc. The organic layer was then dried over
MgSO4, ﬁltered, and evaporated to yield 1-(4-Benzoyl-phenyl)-
ethanone which was used without further puriﬁcation. 1HNMR
(CDCl3): δ 7.88 (d,J =8.1Hz,2H),7.51 (d,J =8.4Hz,2H),7.40
(d, J =7.2Hz, 2H), 7.31 (t, J =6.6Hz, 2H), 7.24 (t, J =6.6Hz,
1H), 2.56 (s, 3H). 13CNMR (CDCl3): δ 197.89, 153.34, 147.13,
135.54, 128.29, 128.24, 127.24, 125.92, 125.76, 26.56. Bromine
(353mg,2.21mmol)wasthenaddedtoasolutionof theketonein
CHCl3 as per the general procedure. The crude α-bromo ketone
was then dissolved in acetone and 2-imino-4-thiobiuret (261mg,
2.21mmol) was added by the general procedure to yield 152mg
(17% over three steps). 1HNMR (DMSO): δ 8.24 (s,br,4H),8.01
(d, J =4.8Hz, 2H), 7.90 (d, J =4.8Hz, 2H), 7.31 (s, 1H), 7.29–
7.21(m,5H). 13CNMR(DMSO):δ197.48,159.77,153.67,145.48,
139.34, 129.71, 129.18, 128.54, 128.03, 127.54, 127.31, 126.16,
108.94. MS, ESI, m/e 404 (MH+).
Synthesis of naphthalene-2-carboxylic acid
[4-(2-guanidino-thiazol-4-yl)-phenyl]-amide, HBr salt (13h)
2-Imino-4-thiobiuret (42mg, 0.353mmol) was added to a
solution Naphthalene-2-carboxylic acid [4-(2-bromo-acetyl)-
phenyl]-amide(130mg,0.353mmol)asperthegeneralprocedure
yielding 33mg (20%). 1HNMR (DMSO): δ 8.62 (s, 1H), 8.24 (s,
br,4H),8.12–7.93 (m,9H),7.72 (s,1H),7.65 (m,2H). 13CNMR
(DMSO): δ 168.281, 160.314, 154.022, 148.829, 139.221, 134.719,
132.955, 130.594, 129.002, 128.626, 128.102, 127.037, 126.323,
126.417, 125.229, 125.016, 119.997, 106.621.
Synthesis of naphthalene-2-carboxylic acid
4-(2-guanidino-thiazol-4-yl)-phenyl ester, HBr salt (13i)
2-Imino-4-thiobiuret (128mg, 1.08mmol) was added to a solu-
tion Naphthalene-2-carboxylic acid 4-(2-bromo-acetyl)-phenyl
ester (400mg, 1.08mmol) as per the general procedure yielding
425mg (84%). 1HNMR (DMSO):δ 8.88 (s,1H),8.22,(s,br,4H),
8.14 (s,2H),8.09 (d,J =8.7Hz,4H),7.84,(s,1H),7.70 (m,2H),
7.43 (d, J =8.7Hz, 2H). 13CNMR (DMSO): δ 164.7191, 161.559,
154.923, 149.112, 140.111, 135.226, 133.558, 130.716, 129.221,
128.447, 128.201, 127.357, 126.273, 126.197, 125.219, 125.196,
120.197, 106.121. MS, ESI, m/e 389 (MH+).
Synthesis of naphthalene-1-carboxylic acid
[4-(2-guanidino-thiazol-4-yl)-phenyl]-amide, HBr salt (13j)
2-Imino-4-thiobiuret (161mg, 1.36mmol) was added to a
solution of Naphthalene-1-carboxylic acid [4-(2-bromo-acetyl)-
phenyl]-amide (500mg, 1.36mmol) in acetone as per the general
procedure which yielded 461mg (72%). 1HNMR (DMSO):δ 8.22
(m, br, 5H), 8.09 (d, J =8.5Hz, 1H), 8.04–8.02 (m, 1H), 7.99 (d,
J =9Hz, 2H), 7.92 (d, J =8.5Hz, 2H). 7.79 (d, J =6.5Hz, 1H),
7.71 (s, 1H), 7.64–7.58 (m, 3H). 13CNMR (DMSO): δ 167.26,
160.24, 153.89, 149.53, 139.35, 134.48, 133.08, 130.17, 129.56,
128.45, 128.30, 126.99, 126.42, 126.33, 125.53, 124.98, 119.72,
106.88.
Synthesis of N-[4-(4-methoxy-phenyl)-thiazol-2-yl]-guanidine, HBr
salt (13m)
2-Imino-4-thiobiuret (695mg, 5.88mmol) was added to
a solution 2-Bromo-1-(4-methoxy-phenyl)-ethanone (1.35g,
5.88mmol) as per the general procedure yielding 1.44g (74%)
of a while solid. 1HNMR (DMSO): δ 8.25 (s, br, 4H), 7.88
(d, J =7.2Hz, 2H), 7.61 (s, 1H), 6.98 (d, J =7.2Hz), 3.79 (s,
3H). 13CNMR (DMSO): δ 159.60,159.27,153.77,149.60,127.35,
125.77, 114.03, 106.02, 55.16.
Synthesis of biphenyl-4-carboxylic acid
4-(2-amino-thiazol-4-yl)-phenyl ester, HI salt (14a)
Thiourea (336.8mg, 4.43mmol) was added to a solution
of Biphenyl-4-carboxylic acid 4-(2-bromo-acetyl)-phenyl ester
(350mg,1.11mmol)inacetoneasperthegeneralprocedureyield-
ing 131.4mg (24%). 1HNMR (DMSO): δ 8.206 (d, J =8.7Hz,
2H), 7.923 (d, J =8.7Hz, 2H), 7.805 (m, 4H), 7.492 (m, 5H),
7.263 (s, 1H). 13CNMR (DMSO): δ 170.111, 164.309, 151.122,
145.5, 138.643, 130.564, 129.969, 129.195, 128.674, 127.492,
127.285, 127.192, 127.092, 122.625, 122.291, 103.028.
Synthesis of 4-tert-butyl-benzoic acid
4-(2-amino-thiazol-4-yl)-phenyl ester, HI salt
Thiourea (256.8mg, 3.374mmol) was added to a solution
of 4-tert-Butyl-benzoic acid 4-acetyl-phenyl ester (500mg,
1.687mmol) in acetone as per the general procedure yielding
247.2mg (30.5%). 1H-NMR (DMSO) δ 8.07 (d,2H ,J =8.4Hz),
7.82 (d,2H ,J =8.6Hz), 7.64 (d,2H ,J =8.2Hz), 7.40 (d,2H ,
J =8.4Hz), 7.23 (s, 1H), 1.33 (s, 1H). 13CNMR (DMSO): δ
170.380, 157.832, 130.377, 130.313, 130.251, 127.625, 126.449,
126.315, 122.987, 122.721, 116.202, 100.889, 35.461, 31.251.
Synthesis of
N-[4-(2-amino-thiazol-4-yl)-phenyl]-4-tert-butyl-benzamide, HBr salt
(14c)
Thiourea (102mg, 1.34mmol) was added to a solu-
tion of N-[4-(2-Bromo-acetyl)-phenyl]-4-tert-butyl-benzamide
(500mg,1.34mmol)inacetoneasperthegeneralprocedureyield-
ing 81.4mg (14%). 1HNMR (DMSO):δ 7.933 (t,J =8.4Hz,4H),
7.613 (d,J =8.7Hz,2H),7.735 (s,1H) 7.536 (d,J =8.7Hz,2H),
1.302 (s, 9H). 13CNMR (DMSO): δ 199.806, 169.829, 166.451,
162.089, 155.367, 141.712, 132.533, 130.025, 128.376, 125.862,
120.491, 31.592.
Synthesis of 4-butyl-benzoic acid 4-(2-amino-thiazol-4-yl)-phenyl
ester, HBr salt (14d)
1HNMR (DMSO) δ 8.16 (s, 3H), 7.91 (m, 6H), 7.65 (s, 1H),
7.34 (d,2H ,J =8.3Hz), 2.65 (t,2H ,J =7.6Hz), 1.58 (td, 2H,
J =7.4Hz, J =15.2Hz), 1.30 (qd, 2H, J =7.2Hz, J =14.3Hz),
0.90 (t,3H ,J =7.3Hz). 13CNMR (DMSO): δ 165.407, 160.801,
154.007, 149.551, 146.321, 139.288, 132.180, 128.323, 128.181,
127.679,126.207,120.117,106.534,34.586,23.803,21.634,13.994.
Synthesis of 4-triﬂuoromethyl-benzenesulfonic acid 4-acetyl-phenyl
ester (15a)
4-(Triﬂuoromethyl)benzene sulfonyl chloride (1g, 4.09mmol)
was added to a solution of 4-hydroxyacetophenone (557mg,
4.09mmol), TEA (1mL) and DMAP (10mg, cat.) in DCM. The
reaction was allowed to stir for 2h and was then quenched with
water and washed with 1M HCl. The organic layer was then dried
over MgSO4, ﬁltered, and evaporated to yield 1.37g (97%) of a
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white solid. 1HNMR (DMSO): δ 8.13 (d,J =8.4Hz,2H),8.07 (d,
J =8.7Hz,2H),7.99(d,J =8.7Hz,2H),7.24(d,J =8.7Hz,2H),
2.56 (s,3H). 13CNMR (DMSO): δ 196.67,151.79,135.82,130.40,
129.30, 127.09, 122.24, 26.72.
Synthesis of toluene-4-sulfonic acid 4-acetyl-phenyl ester (15b)
p-Toluenesulfonyl chloride (1g, 5.25mmol) was added to a solu-
tionof 4-hydroxyacetophenone(715mg,5.25mmol),TEA(1mL)
andDMAP(10mg,cat.)inDCM.Thereactionwasallowedtostir
for 2h and was then quenched with water and washed with 1M
NaOH. The organic layer was then dried over MgSO4, ﬁltered,
and evaporated to yield 1.52g (100%) of a white solid. 1HNMR
(DMSO):δ7.96(d,J =8.7Hz,2H),7.76(d,J =8.4Hz,2H),7.48
(d,J =8.1Hz,2H),7.17 (d,J =8.7Hz,2H),2.55 (s,3H),2.42 (s,
3H).
Synthesis of 4-tert-butyl-benzenesulfonic acid 4-acetyl-phenyl ester
(15c)
4-tert-Butylbenzene sulfonyl chloride (1g,4.29mmol) was added
to a solution of 4-hydroxyacetophenone (585mg, 4.29mmol),
TEA (1mL), and DMAP (10mg, cat.) in DCM. The reaction
was allowed to stir for 2h and was then quenched with water
and washed with 1M NaOH. The organic layer was then dried
over MgSO4, ﬁltered, and evaporated to yield 1.40g (98%) of a
white solid. 1HNMR (CDCl3): δ 7.90 (d,J =8.5Hz,2H),7.75 (d,
J =9Hz, 2H), 7.53 (d, J =10.5Hz, 2H), 7.10 (d, J =9Hz, 2H),
2.57 (s, 3H), 1.34 (s, 9H). 13CNMR (CDCl3): δ 196.90, 158.94,
153.18, 135.87, 132.31, 130.27, 128.53, 126.54, 122.71, 105.86,
35.62, 31.22, 26.87.
Synthesis of biphenyl-4-sulfonic acid 4-acetyl-phenyl ester (15d)
A solution of phenylboronic acid (172mg,1.41mmol),4-bromo-
benzenesulfonic acid 4-acetyl-phenyl ester (500mg, 1.41mmol)
and Cs2CO3 (691mg,2.12mmol) in 3:1 DME:H2O was degassed
for 15min. Pd(PPh3)4 (82mg, 0.071mmol) was then added and
the solution was heated to 80˚C for 6h. The solution was then
diluted with DCM, ﬁltered through Celite, and extracted twice
withDCM.TheorganiclayerwasthendriedoverMgSO4,ﬁltered,
and evaporated to an oil that was puriﬁed on a silica gel column
(3:1 Hex:EtOAc) to yield 258mg (52%). 1HNMR (CDCl3): δ 7.91
(t,J =9Hz,3H),7.75 (d,J =7.5Hz,2H),7.62 (d,J =8Hz,2H),
7.50(t,J =7.5Hz,2H),7.45(t,J =6.5Hz,2H),7.14(d,J =8Hz,
2H), 2.58 (s, 3H). 13CNMR (CDCl3): δ 196.04, 154.10, 152.91,
147.67, 136.00, 133.76, 130.10, 129.16, 128.97, 127.78, 127.36,
122.51, 121.77, 26.63.
Synthesis of bistoluene-4-sulfonic acid 4-acetyl-phenyl amide (15f)
p-Toluenesulfonyl chloride (1g, 5.25mmol) was added to a solu-
tion of 4-aminoacetophenone (710mg, 5.25mmol), TEA (1mL)
and DMAP (10mg, cat.) in DCM. The reaction was allowed to
stir for 2h and was then quenched with water and washed with
1M HCl. The organic layer was then dried over MgSO4, ﬁltered,
and evaporated to yield 1.04g (69%) of a white solid. 1HNMR
(DMSO):δ8.00(d,J =8.4Hz,2H),7.70(d,J =8.4Hz,4H),7.49
(d,J =8.4Hz,4H),7.16 (d,J =8.4Hz,2H),2.61 (s,3H),2.45 (s,
6H). MS, ESI, m/e 444 (MH+).
Synthesis of 4-tert-butyl-benzenesulfonic acid 3-acetyl-phenyl ester
(15g)
4-tert-Butyl-benzenesulfonylchloride(1g,4.29mmol)wasadded
to a solution of 3-aminoacetophenone (585mg,4.29mmol),TEA
(1mL)andDMAP(10mg,cat.)inDCM.Thereactionwasallowed
to stir for 2h and was then quenched with water and washed with
1M HCl. The organic layer was then dried over MgSO4, ﬁltered,
and evaporated to yield 1.37g (96%) of a white solid. 1HNMR
(CDCl3) δ 7.84 (d, 1H, J=7.7Hz), 7.75 (d,2H ,J =8.4Hz), 7.54
(d,2H,J =8.4Hz),7.44 (s,1H),7.41 (d,1H,J =7.9Hz),7.26 (s,
1H), 2.49 (s, 2H), 1.34 (s, 9H). 13CNMR (DMSO): δ 196.300,
158.650, 149.707, 138.496, 131.941, 129.914, 128.351, 127.116,
126.757, 126.235, 122.187, 35.351, 30.944, 26.539.
Synthesis of 4-triﬂuoromethyl-benzenesulfonic acid
4-(2-guanidino-thiazol-4-yl)-phenyl ester, HBr salt (17a)
Bromine (634mg, 3.97mmol) was added to a solution of
4-Triﬂuoromethyl-benzenesulfonic acid 4-acetyl-phenyl ester
(1.37g, 3.97mmol) in CHCl3 as per the general procedure which
was carried on crude. 2-Imino-4-thiobiuret (469mg, 3.97mmol)
wasaddedtoasolutionof4-Triﬂuoromethyl-benzenesulfonicacid
4-(2-bromo-acetyl)-phenyl ester (1.68g, 3.97mmol) in acetone
and brought to reﬂux as per the general procedure to yield 1.31g
(63% over two steps). 1HNMR (DMSO): δ 8.21 (s, br, 4H), 8.12
(d, J =8.7Hz, 2H), 8.08 (d, J =8.7Hz, 2H), 8.00 (d, J =9Hz,
2H), 7.83 (s, 1H), 7.13 (d, J =8.7Hz, 2H). 13CNMR (DMSO):
δ 159.99, 153.63, 148.36, 148.26, 138.01, 132.44, 129.38, 127.72,
127.00, 122.36, 109.48.
Synthesis of toluene-4-sulfonic acid
4-(2-guanidino-thiazol-4-yl)-phenyl ester, HBr salt (17b)
Bromine(826mg,5.17mmol)wasaddedtoasolutionof toluene-
4-sulfonic acid 4-acetyl-phenyl ester (1.5g, 5.17mmol) in CHCl3
asperthegeneralprocedurewhichwascarriedoncrude.2-Imino-
4-thiobiuret (611mg, 5.17mmol) was added to a solution of
toluene-4-sulfonic acid 4-(2-bromo-acetyl)-phenyl ester (1.91g,
5.17mmol) in acetone and brought to reﬂux as per the general
proceduretoyield1.71g(71%overtwosteps). 1HNMR(DMSO):
δ 8.20 (s, br, 4H), 7.97 (d, J =8.7Hz, 2H), 7.81 (s, 1H), 7.75
(d, J =8.1Hz, 2H), 7.47 (d, J =8.4Hz, 2H), 7.06 (d, J =9Hz,
2H), 2.42 (s, 3H). 13CNMR (DMSO): δ 159.97, 153.64, 148.65,
148.38, 145.83, 132.08, 131.21, 130.21, 128.23, 127.54, 122.35,
109.26, 21.13. MS, ESI, m/e 389 (MH+).
Synthesis of 4-tert-butyl-benzenesulfonic acid
4-(2-guanidino-thiazol-4-yl)-phenyl ester, HBr salt (17c)
Bromine (673mg, 4.21mmol) was added dropwise to a solu-
tion of 4-tert-Butyl-benzenesulfonic acid 4-acetyl-phenyl ester
(1.40mg,4.21mmol)inCHCl3 asperthegeneralprocedurewhich
yielded 1.73g (100%) which was carried on crude. 2-Imino-4-
thiobiuret (497mg, 4.21mmol) was added to a solution of 4-
tert-butyl-benzenesulfonic acid 4-(2-bromo-acetyl)-phenyl ester
(1.73g, 4.21mmol) as per the general procedure which yielded
1.76g (81% over two steps). 1HNMR (DMSO): δ 8.22 (s,br,4H),
7.98 (d, J =8.7Hz, 2H), 7.28–7.80 (m, 3H), 7.69 (d, J =8.7Hz,
2H), 7.10 (d, J =8.7Hz, 2H), 1.30 (s, 9H). 13CNMR (DMSO):
δ 159.89, 158.23, 153.65, 148.62, 148.37, 132.05, 131.48, 128.02,
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127.55, 126.61, 122.22, 109.24, 35.07, 30.56. MS, ESI, m/e 431
(MH+).
Synthesis of biphenyl-4-sulfonic acid
4-(2-guanidino-thiazol-4-yl)-phenyl ester, HBr salt (17d)
Bromine(113mg,0.71mmol)wasaddedtoasolutionofbiphenyl-
4-sulfonic acid 4-acetyl-phenyl ester (250mg, 0.71mmol) in
CHCl3 as per the general procedure which was carried on crude.
2-Imino-4-thibiuret (84mg, 0.71mmol) was added to a solu-
tion of biphenyl-4-sulfonic acid 4-(2-bromo-acetyl)-phenyl ester
(306mg,0.71mmol)inacetoneasperthegeneralprocedurewhich
yielded 60mg (16% over two steps). 1HNMR (DMSO): δ 8.19 (s,
br,4H),8.01–7.95(m,6H),7.79(t,J =6.6Hz,3H),7.50(m,3H),
7.12 (d, J =8.7Hz, 2H). 13CNMR (DMSO): δ 153.62, 148.60,
142.74, 137.63, 132.76, 132.167, 129.19, 129.05, 128.91, 127.75,
127.59, 127.16, 122.40, 118.45, 114.76, 109.32.
Synthesis of 5-dimethylamino-naphthalene-1-sulfonic acid
4-(2-guanidino-thiazol-4-yl)-phenyl ester, HBr salt (17e)
Dansyl chloride (750mg, 2.78mmol) was added to a solution of
4-hydroxyacetophenone (379mg, 2.78mmol), TEA (1mL) and
DMAP (10mg, cat.) in DCM. The reaction was allowed to stir
for 2h and was then quenched with water and washed with 1M
NaOH. The organic layer was then dried over MgSO4, ﬁltered,
andevaporatedtoyieldayellowsolidwhichwascarriedoncrude.
1HNMR (CDCl3): δ 8.60 (d, J =8.4Hz, 1H), 8.45 (d, J =8.7Hz,
1H), 8.07 (d, J =7.5Hz, 1H), 7.79 (d, J =8.7Hz, 2H), 7.68 (t,
J =7.8Hz,1H),7.44(t,J =7.5Hz,1H),7.25(d,J =7.5Hz,1H),
6.99 (d, J =8.7Hz, 2H), 2.91 (s, 6H), 2.51 (s, 3H). 13CNMR
(CDCl3): δ 196.56, 152.99, 151.97, 135.57, 132.28, 131.27, 130.56,
129.94,129.70,129.19,122.90,122.16,119.15,115.69,45.40,26.56.
Bromine (444mg,2.78mmol) was then added to a solution of the
ketone (1.02g,2.78mmol) in CHCl3 as per the general procedure
andwascarriedoncrude.2-imino-4-thiobiuret(328.5mg,bromo
ketone in acetone as per 2.78mmol) was then added to a solution
of the general procedure which yielded 203mg (13% over three
steps) of a yellow solid. 1HNMR (DMSO): δ 8.70 (d, J =8.4Hz,
1H), 8.61 (d, J =8.7Hz, 1H), 8.40 (d, J =9Hz, 1H), 8.31 (d,
J =8.4Hz, 1H), 8.16 (s, br, 4H), 8.08 (t, J =6.9Hz, 1H), 7.91–
7.86(m,2H),7.75(d,J =3Hz,1H),6.93(t,J =8.7Hz,2H),3.00
(s, 3H), 2.87 (s, 3H).
Synthesis of bistoluene-4-sulfonic acid
4-(2-guanidino-thiazol-4-yl)-phenyl amide, HBr salt (17f)
Bromine (553mg, 3.46mmol) was added to a solution of
bistoluene-4-sulfonicacid4-acetyl-phenylamide(1g,3.46mmol)
inCHCl3 asperthegeneralprocedurewhichwascarriedoncrude.
2-Imino-4-thiobiuret (409mg, 3.46mmol) was added to a solu-
tion of toluene-4-sulfonic acid 4-(2-bromo-acetyl)-phenyl ester
(1.27g, 3.46mmol) in acetone and brought to reﬂux as per the
general procedure to yield 992mg (46% over two steps). 1HNMR
(DMSO): δ 8.20 (s, br, 4H), 8.02 (d, J =8.4Hz, 2H), 7.90 (s,
1H), 7.71 (d, J =8.4Hz, 4H), 7.49 (d, J =8.4Hz, 4H), 7.03 (d,
J =8.7Hz,2H),2.45(s,6H). 13CNMR(DMSO):δ160.56,153.79,
148.33, 145.43, 135.60, 134.73, 133.01, 131.52, 129.95, 127.98,
126.90, 110.21, 21.14. MS, ESI, m/e 542 (MH+).
Synthesis of 4-tert-butyl-benzenesulfonic acid
3-(2-guanidino-thiazol-4-yl)-phenyl ester, HBr salt (17g)
Bromine (660mg, 4.12mmol) was added to a solution of
4-tert-Butyl-benzenesulfonic acid 3-acetyl-phenyl ester (1.37g,
4.12mmol) in CHCl3 as per the general procedure which was car-
ried on crude. 2-Imino-4-thiobiuret (472.6mg, 4.00mmol) was
added to a solution of 4-tert-Butyl-benzenesulfonic acid 3-(2-
bromo-acetyl)-phenyl ester (1.645g, 4.00mmol) in acetone and
brought to reﬂux as per the general procedure to yield 1.383g
(65% over two steps). 1HNMR (DMSO) δ 8.23 (s, 4H), 7.90 (d,
1H,J =7.8Hz),7.79(d,2H,J =3.5Hz),7.67(d,2H,J =8.6Hz),
7.44(t,1H,J =8.0Hz),7.01(dd,1H,J =2.3Hz,J =8.2Hz),1.26
(s,9H). 13CNMR (DMSO): δ 159.938,158.231,153.610,149.348,
134.719, 131.183, 130.296, 128.175, 126.5253, 124.736, 121.514,
119.653, 109.768, 35.033, 33.479.
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